Acute mountain sickness (AMS) is a common form of altitude sickness which affects between 10 to 80% of individuals climbing to high altitudes [1] [2] [3] [4] [5]. Symptoms are variable and usually commence within 24 hours of an unacclimatized individual ascending rapidly to altitudes > 8000 feet. Common symptoms include headaches, dizziness, vomiting, anorexia, fatigue, and insomnia [6] and they are due to the hypoxic and hypobaric environment at high altitudes [7]. Other symptoms like loss of appetite, light-headedness, lassitude, dyspnea and delirium may also be present. Some patients experience worsening of symptoms with the development of either cerebral edema (HACE - high altitude cerebral edema) and/or high altitude pulmonary edema (HAPE). But in a majority of the cases, the symptoms of AMS usually improve after a day unless the patient ascends again to a higher altitude, in which case the symptoms can worsen.

The clinician can diagnose AMS on the basis of the patient's clinical presentation, history, and physical examination findings. History will reveal recent ascent to high altitude by the unacclimatized patient while physical examination may reveal tachycardia, tachypnea, and pulmonary rales if the patient is developing pulmonary edema. Laboratory tests like complete blood count may be abnormal with elevated hematocrit, and erythrocytosis while arterial blood gas analysis will reveal respiratory alkalosis. Pulse oximetry values do not usually indicate the severity of AMS and are therefore not useful in either detecting or in the management of the condition although they may help to detect HAPE. An electrocardiogram may show variable features like right axis deviation, non-specific ST-T changes, sinus arrhythmias, and P wave abnormalities. Chest radiography is indicated only in patients suspected clinically to have HAPE.

The diagnosis and severity of AMS can be assessed using the Lake Louise score (LLS) [8] as well as the Environmental Symptoms Questionnaire (ESQ) [9] [10]. The LLS was developed by a consensus conference on Hypoxia and Mountain Medicine in 1991 and consists of a self-reported score which is the sum of responses to five questions [8] and can be verified by a clinician during an interview. The ESQ consists of an inventory of expected physiological and psychological symptoms and was developed by the United States army. A part of this inventory containing symptoms indicative of cerebral hypoxia (AMS-C) is used to assess AMS [11]. However, the two questionnaires do not corroborate to provide an identical diagnosis [12] and as yet there is no gold standard tool for the assessment of AMS [13] [14].

Despite the presence of AMS symptoms, magnetic resonance imaging does not detect brain edema or an increase in brain volume for up to 12 hours after hypoxia and is therefore not helpful in the diagnosis and management of AMS [14].

The primary treatment for AMS is to stop further ascent and, if possible, descend to a lower altitude. Rest and hydration are crucial, and over-the-counter pain relievers can help alleviate headaches. In more severe cases, supplemental oxygen or medications such as acetazolamide (which helps the body acclimatize) may be prescribed. Severe AMS may require immediate descent and medical attention.

The prognosis for individuals with AMS is generally good, especially if the condition is recognized early and managed appropriately. Most symptoms resolve within a few days with rest and acclimatization. However, if left untreated, AMS can progress to more serious conditions such as High Altitude Cerebral Edema (HACE) or High Altitude Pulmonary Edema (HAPE), which can be life-threatening.

AMS is caused by the body's inability to adapt quickly to the lower oxygen levels and reduced air pressure at high altitudes. The exact mechanisms are not fully understood, but it is believed that hypoxia (low oxygen levels) leads to changes in blood flow and fluid balance in the brain, resulting in the symptoms of AMS.

AMS is a common condition among individuals who travel to high altitudes, affecting up to 50% of those who ascend rapidly to elevations above 8,000 feet. It can affect people of all ages and fitness levels, although some individuals may be more susceptible due to genetic factors or previous experiences with altitude sickness.

The pathophysiology of AMS involves the body's response to hypoxia at high altitudes. Reduced oxygen levels lead to increased blood flow to the brain, which can cause swelling and increased pressure. This, in turn, results in the symptoms associated with AMS. The body's acclimatization process, which includes increased breathing rate and red blood cell production, helps mitigate these effects over time.

Preventing AMS involves gradual acclimatization to high altitudes. This can be achieved by ascending slowly, allowing the body time to adjust to the changing conditions. Staying well-hydrated, avoiding alcohol, and eating a high-carbohydrate diet can also help. In some cases, medications like acetazolamide may be used prophylactically to aid acclimatization.

Acute Mountain Sickness is a common condition that occurs when individuals ascend to high altitudes too quickly. It is characterized by symptoms such as headache, nausea, and fatigue. Early recognition and management, including rest and descent, are crucial to prevent complications. With proper acclimatization and preventive measures, AMS can often be avoided.

If you are planning to travel to high altitudes, it's important to be aware of the symptoms of Acute Mountain Sickness. These include headache, nausea, dizziness, and fatigue. To reduce your risk, ascend gradually, stay hydrated, and avoid alcohol. If you experience symptoms, stop ascending and rest. In severe cases, descend to a lower altitude and seek medical attention. Remember, AMS can affect anyone, so being prepared and informed is key to a safe and enjoyable high-altitude experience.

1. Gertsch JH, Seto TB, Mor J, Onopa J. Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. High altitude medicine & biology. 2002;3(1):29–37.
2. Honigman B, Theis MK, Koziol-McLain J, et al. Acute mountain sickness in a general tourist population at moderate altitudes. Ann Intern Med. 1993;118(8):587–92.
3. Karinen H, Peltonen J, Tikkanen H. Prevalence of acute mountain sickness among Finnish trekkers on Mount Kilimanjaro, Tanzania: an observational study. High altitude medicine & biology. 2008;9(4):301–6.
4. Maggiorini M, Buhler B, Walter M, Oelz O. Prevalence of acute mountain sickness in the Swiss Alps. BMJ. 1990;301(6756):853–5.
5. Murdoch DR. Altitude Illness Among Tourists Flying to 3740 Meters Elevation in the Nepal Himalayas. J Travel Med. 1995;2(4):255–6.
6. Barry PW, Pollard AJ. Altitude illness. BMJ. 2003;326(7395):915–9.
7. Gallagher SA, Hackett PH. High-altitude illness. Emerg Med Clin North Am. 2004;22(2):329–55.
8. Roach RC, Bartsch P, Hackett PH, Oelz O. The Lake Louise acute mountain sickness scoring system, in Hypoxia and Molecular Medicine. Queens City Press, Burlington, Va, USA, 1993; pp. 272–274.
9. Kobrick JL, Sampson JB. New inventory for the assessment of symptom occurrence and severity at high altitude. Aviation Space and Environmental Medicine. 1979; 50: 9: 925–929
10. Sampson JB, Kobrick JL. The environmental symptoms questionnaire: revisions and new filed data. Aviation Space and Environmental Medicine. 1980; 51: 9 (1): 872–877
11. Beidleman BA, Muza SR, Fulco CS, Rock PB, Cymerman A. Validation of a shortened electronic version of the environmental symptoms questionnaire. High Altitude Medicine and Biology, 2007; 8 (3): 192–199.
12. Wagner DR, Teramoto M, Knott JR, Fry JP. Comparison of scoring systems for assessment of acute mountain sickness. High Altitude Medicine and Biology. 2012; 13 (4): 245–251.
13. Roach RC, Kayser B. Measuring mountain maladies. High Altitude Medicine and Biology. 2007; 8 (3): 171–172
14. Bartsch P, Bailey DM, Berger MM, Knauth M, Baumgartner RW. Acute mountain sickness: controversies and advances. High Altitude Medicine & Biology. 2004; 5: (2): 110–124.